Alnylam’s John Maraganore isn’t the only CEO to leave his post; CRISPR’s chief commercial officer takes the helm at a protein degradation player – Endpoints News

The de­par­ture of a num­ber of CEOs is the pre­vail­ing theme that kicks off this week’s in­stall­ment: In a stun­ner, Al­ny­lam CEO John Maraganore an­nounced that Yvonne Green­street will be his suc­ces­sor at the end of the year. Maraganore, the Cam­bridge, MA biotech’s found­ing chief ex­ec­u­tive since 2002 who has helped in­vig­o­rate the RNAi space, will step in­to a con­sult­ing role un­til March 31 and main­tain his pres­ence in the com­pa­ny as a mem­ber of the sci­en­tif­ic ad­vi­so­ry board.

Maraganore told our John Car­roll a cou­ple years back that re­tire­ment wasn’t on the ta­ble, but in­stead Al­ny­lam will be led by Green­street, who re­placed cur­rent Sage CEO Bar­ry Greene as the com­pa­ny’s pres­i­dent in Au­gust 2020 and is al­so COO.

This week, Al­ny­lam un­spooled pos­i­tive da­ta for what the biotech hopes will be­come its fourth RNAi ap­proval with its drug vutrisir­an for polyneu­ropa­thy as­so­ci­at­ed with hered­i­tary transthyretin-me­di­at­ed (hAT­TR) amy­loi­do­sis. Lumasir­an (mar­ket­ed as Oxlu­mo) was ap­proved in No­vem­ber 2020.

Mean­while, the search is un­der­way for a per­ma­nent CEO to re­place Bar­ry Labinger at can­cer-fo­cused Check­mate Phar­ma­ceu­ti­cals, while board mem­ber Alan Fuhrman steps up to the plate on an in­ter­im ba­sis. Labinger suc­ceed­ed founder and cur­rent CSO Art Krieg in De­cem­ber 2018 and steered Check­mate to a $75 mil­lion IPO in Ju­ly 2020 with a heavy re­liance on its TLR9 ag­o­nist vidu­tolimod (CMP-001), but the stock price has dwin­dled sig­nif­i­cant­ly since its Nas­daq de­but. Fuhrman, the CFO for Am­plyx from 2017-20, is a mem­ber of the board of di­rec­tors at Spring­Works Ther­a­peu­tics and Es­pe­ri­on.

Start­ing Nov. 8, there will al­so be a change at the top of South San Fran­cis­co T cell en­gager biotech Har­poon Ther­a­peu­tics, with Julie East­land suc­ceed­ing Jer­ry McMa­hon as CEO. McMa­hon, who an­nounced his res­ig­na­tion this week, had been Har­poon’s chief ex­ec­u­tive since De­cem­ber 2016 and presided over a com­pa­ny in de­cline af­ter its prostate can­cer can­di­date HPN424 mas­sive­ly un­der­whelmed in a Phase I/IIa study, gut­ting the stock price. Be­fore ac­cept­ing her first CEO job, East­land held dual roles as COO and CFO at Re­Code Ther­a­peu­tics and cur­rent­ly has board seats at Gray­bug Vi­sion and Dy­navax.

Last­ly in this group, Jed Latkin has re­signed from his three-pronged re­spon­si­bil­i­ties of CEO, CFO and COO at Dublin, OH-based Navidea Bio­phar­ma­ceu­ti­cals, a biotech con­cen­trat­ing on pre­ci­sion im­mun­odi­ag­nos­tic agents. Navidea has set up an Of­fice of the CEO un­til a suc­ces­sor is named, com­prised of three board mem­bers and two ex­ecs: chair­man Alexan­der Cap­pel­lo, vice chair John Scott, Thomas Farb (who was just ap­point­ed to the board with Ag­niesz­ka Win­kler ef­fec­tive Oct. 7), CMO Michael Rosol, and VP of fi­nance and ad­min­is­tra­tion Eri­ka Eves.

---

→ CRISPR Ther­a­peu­tics chief com­mer­cial of­fi­cer Philippe Drou­et has ex­it­ed stage left to take on the CEO job at Bio­Th­eryX, a pro­tein degra­da­tion out­fit based in San Diego that gath­ered up a Se­ries E round in May. Drou­et didn’t stick around at CRISPR for very long — he was named CCO in Feb­ru­ary af­ter five years at Mer­ck, where he had been in­te­gral to the launch of Keytru­da as the drug gi­ant’s SVP, on­col­o­gy glob­al mar­ket­ing & mar­ket ac­cess. While with No­var­tis, Drou­et wore sev­er­al hats, from head of on­col­o­gy mar­ket­ing in Cana­da to VP of the US hema­tol­ogy fran­chise.

→ Swedish on­col­o­gy play­er Medi­vir has tapped As­traZeneca alum Jens Lind­berg as CEO while Mag­nus Chris­tensen stays on as in­ter­im CEO un­til Lind­berg takes over “with­in six months,” ac­cord­ing to the re­lease. Lind­berg, the act­ing CEO and VP of com­mer­cial at Sedana Med­ical, held a se­ries of posts in near­ly a quar­ter cen­tu­ry at As­traZeneca that cul­mi­nat­ed in his role as VP of on­col­o­gy in the Nordic-Baltic re­gion. There’s been a re­volv­ing door late­ly at the top spot at Medi­vir af­ter Uli Hack­sell re­placed Chris­tine Lind in 2018 and the com­pa­ny slashed 60 oth­er jobs in the process. In Sep­tem­ber 2020, Yil­maz Mahshid be­came Medi­vir’s CEO but bolt­ed abrupt­ly to take the CFO job at Egetis Ther­a­peu­tics.

→ The FDA’s ap­proval of Fab­razyme in March forced lentivi­ral gene ther­a­py out­fit Avro­bio to go back to the draw­ing board with its own Fab­ry dis­ease drug, so it would seem the pro­mo­tion of Es­s­ra Rid­ha to CMO is an im­por­tant step to­ward giv­ing AVR-RD-01 the stur­dy foot­ing it needs. Pri­or to her pre­vi­ous re­spon­si­bil­i­ties as Avro­bio’s VP, clin­i­cal de­vel­op­ment, Rid­ha was se­nior med­ical di­rec­tor, clin­i­cal sci­ences, gene edit­ed cell ther­a­py dur­ing al­most two years at Sang­amo. She al­so had a three-year run at Glax­o­SmithK­line, tak­ing on the role of clin­i­cal de­vel­op­ment di­rec­tor, cell & gene ther­a­py, rare dis­eases.

→ In an­oth­er case of the band get­ting back to­geth­er, Loret­ta Itri has been named CMO at Aa­di Bio­science, which re­verse merged with Aer­pio Ther­a­peu­tics in May and where ex-Im­munomedics CEO Be­hzad Ag­haz­adeh is a board mem­ber. Like Aa­di’s new­ly-ar­rived COO, Bren­dan De­laney, Itri is an Im­munomedics alum, hav­ing been CMO when Gilead opened up the pock­et­book to pur­chase the biotech for $21 bil­lion last year. She’s al­so served as EVP of glob­al health sci­ences and reg­u­la­to­ry af­fairs at The Med­i­cines Com­pa­ny.

→ Be­gin­ning its odyssey to solve the tran­scrip­tion fac­tor puz­zle with an $82 mil­lion Se­ries A in May, Third Rock biotech Flare Ther­a­peu­tics has se­lect­ed Daphne Kary­das as COO and CFO, while Michaela Bow­den gets the nod as SVP of bi­ol­o­gy and trans­la­tion. Kary­das is an Al­ler­gan alum in cor­po­rate fi­nan­cial plan­ning and in­vestor re­la­tions who just com­plet­ed a year as CFO of Syn­dax Phar­ma­ceu­ti­cals, and Bow­den spent the last three years at Bris­tol My­ers Squibb, leav­ing the drug gi­ant as ex­ec­u­tive di­rec­tor of trans­la­tion­al bi­ol­o­gy.

→ Low­ell, MA neu­ro biotech Al­cy­one Ther­a­peu­tics broke through in June with a $23 mil­lion Se­ries A and a game plan to tack­le Rett syn­drome out of the gates. CEO PJ Anand has now sur­round­ed him­self with four new ex­ecs in this ef­fort, with CMO and glob­al head of R&D Ot­tavio Vi­to­lo lead­ing off. The for­mer head of neu­ro­mus­cu­lar clin­i­cal re­search at Pfiz­er, Vi­to­lio co-found­ed Vitem Ther­a­peu­tics and was CMO and R&D chief at Rel­ma­da Ther­a­peu­tics from 2018-20.

Who else is join­ing Vi­to­lo? Cred­it Su­isse and Cowen vet Ravi Mehro­tra (CFO and head of strat­e­gy) re­cent­ly worked with Umer Raf­fat and Josh Schim­mer as se­nior man­ag­ing di­rec­tor of Ever­core’s health­care re­search team. Su­san D’Cos­ta (EVP and glob­al head of tech­nol­o­gy) comes to Al­cy­one from Ther­mo Fish­er, where she was se­nior di­rec­tor, tech­ni­cal pro­gram de­sign. And Rachel Salz­man (EVP of port­fo­lio, ex­ter­nal af­fairs & de­vel­op­ment) found­ed and was pres­i­dent and CEO of CNS gene ther­a­py out­fit Swan­Bio.

→ Mak­ing its push in­to the Eu­ro­pean mar­ket, Amy­lyx has ap­point­ed Stéphanie Hoff­mann-Gen­de­bi­en as head, gen­er­al man­ag­er in Eu­rope, the Mid­dle East and Africa (EMEA). Hoff­mann-Gen­de­bi­en, a long­time Gen­zyme staffer, was a man­ag­ing di­rec­tor and found­ing part­ner at GH Part­ners since 2019, when she left rare dis­ease biotech Clemen­tia Phar­ma­ceu­ti­cals as VP, gen­er­al man­ag­er, EMEA af­ter Ipsen snapped it up for $1.3 bil­lion. Co-led by Justin Klee and Josh Co­hen, Amy­lyx said in April that they planned on sub­mit­ting a mar­ket­ing ap­pli­ca­tion to the EMA by the end of the year for its ALS can­di­date AMX0035, and af­ter the FDA ini­tial­ly balked at an NDA, the agency did a 180 on the re­quest in Sep­tem­ber.

→ Fo­cus­ing on the blood-brain bar­ri­er, Travec­ta Ther­a­peu­tics named Charles Ryan pres­i­dent and CEO in June af­ter helm­ing Neu­rotrope. Ryan has now fleshed out his lead­er­ship team with a big batch of ex­ecs and board mem­bers, start­ing with CMO and head of R&D Don­ald Man­ning, a No­var­tis and Cel­gene vet who was CMO at Sh­iono­gi and then Ad­ynxx from 2012-20. Pe­ter Mil­li­gan (CFO) was pre­vi­ous­ly the fi­nance chief at Ex­elis, G&W Lab­o­ra­to­ries and most re­cent­ly Melin­ta, a role cur­rent­ly held by Su­san Blum. Pe­ter Tate (head of Sin­ga­pore op­er­a­tions and se­nior di­rec­tor, busi­ness de­vel­op­ment), a one-time Pfiz­er sci­en­tist, wrapped up a 10-year as­so­ci­a­tion with EMD Serono in 2020 as the Mer­ck KGaA sub’s as­so­ciate di­rec­tor, phar­ma­ceu­ti­cal tech­nolo­gies. Pe­ter Honig jumps to Travec­ta’s sci­en­tif­ic ad­vi­so­ry board af­ter re­tir­ing from Pfiz­er as head of glob­al reg­u­la­to­ry af­fairs and group head of de­vel­op­ment for Chi­na and Japan.

Fi­nal­ly, Ryan will oc­cu­py a seat on Travec­ta’s board of di­rec­tors along­side for­mer Al­ler­gan ex­ec June Bray, Ivan Gergel, Pas­cal Heber­ling and Bob Huang.

→ You may re­call Tri­umvi­ra’s lead­er­ship moves in April, when the Paul Lam­mers-led T cell biotech named Tere­sa McRoberts as CFO and pro­mot­ed An­dreas Bad­er and Jon Irvin to CSO and VP of fi­nance, re­spec­tive­ly. Tri­umvi­ra has found a CMO this week, and it’s Deyaa Adib, who was just the act­ing CMO for Rain Ther­a­peu­tics and has been VP of late-stage de­vel­op­ment at Blue­print Med­i­cines. A Sanofi and Astel­las vet, Adib served as Bax­al­ta’s glob­al ther­a­peu­tics head for sol­id tu­mors. In Au­gust 2020, Tri­umvi­ra nabbed $55 mil­lion in a Se­ries A that “will give us a nice run­way to do a lot of fun stuff,” as Lam­mers said at the time, with its T cell anti­gen cou­pler (TAC) tech­nol­o­gy.

→ On­chilles Phar­ma has hired a slew of new faces to its lead­er­ship team with the ap­point­ments of Christo­pher Twit­ty (CSO); In­grid Joseph (SVP, pre­clin­i­cal de­vel­op­ment); and So­nia Feau (di­rec­tor of bi­ol­o­gy). Twit­ty brings with him ex­pe­ri­ence from his time at Bay­er, Cell Genesys, Toca­gen and On­coSec Med­ical. Mean­while, Joseph served as VP of phar­ma­col­o­gy and tox­i­col­o­gy at Syn­thorx; se­nior di­rec­tor of phar­ma­col­o­gy and bioimag­ing at Astel­las; and di­rec­tor of on­cophar­ma­col­o­gy at Bio­gen. Last, but not least, Feau joins from On­corus, where she served as as­so­ciate di­rec­tor of im­munol­o­gy. Pri­or to that stint, Feau was with Mer­ck and Mer­ri­mack Phar­ma­ceu­ti­cals.

→ Ger­man CD­MO Rentschler Bio­phar­ma, which will have a pres­ence at the Cell and Gene Ther­a­py Cat­a­pult in the UK by next year, has ap­point­ed Robert Pant­i­ng as gen­er­al man­ag­er of Rentschler ATMP, Cen­ter of Ex­cel­lence for Cell and Gene Ther­a­py. Pri­or to Rentschler, Pant­i­ng spent a decade at Fu­ji­film Diosynth Biotech­nolo­gies, where he most re­cent­ly served as pres­i­dent for pro­gram man­age­ment and sales & op­er­a­tions plan­ning.

→ Bryan Jen­nings is mak­ing his way over to Noxxon Phar­ma as the com­pa­ny’s new CFO. Jen­nings brings aboard ex­pe­ri­ence from his time as CFO at Pep­ti­log­ics, KAHR Bio, Beren Ther­a­peu­tics, Ra­tio­nal Vac­cines and ChemomAb. In ad­di­tion to those stints, Jen­nings was CFO and CEO at Vista Cap­i­tal Ad­vi­sors and was with Mor­gan Stan­ley as man­ag­ing di­rec­tor, head of cap­i­tal mar­kets and risk man­age­ment.

→ Af­ter just bring­ing aboard Ma­son Free­man as EVP, clin­i­cal de­vel­op­ment last week, Cin­Cor Phar­ma has now added Ter­ry Coel­ho to its ranks as EVP, CFO and chief busi­ness de­vel­op­ment of­fi­cer. Coel­ho joins the Cincin­nati-based biotech from BioDe­liv­ery Ser­vices In­ter­na­tion­al, where she served as EVP and CFO. Pri­or to that, Coel­ho was CFO of Balchem Corp, CFO and COO of Di­versey, and held lead­er­ship roles with No­var­tis.

→ Pep­Gen, the Boston-based Ox­ford spin­out that re­ceived $112.5 mil­lion in Se­ries B fi­nanc­ing back in Au­gust for its lead pro­grams in mus­cu­lar dy­s­tro­phy, has ap­point­ed Noel Don­nel­ly as CFO. Don­nel­ly has spent much of his ca­reer at Shire, where he has served as VP, R&D busi­ness and strat­e­gy and, most re­cent­ly, as head of R&D fi­nance.

→ Whole Lot­ta love: Lot­ta Ferm will be an in­ter­im CFO no more at Swedish can­cer biotech Im­mu­nicum, tak­ing over on a per­ma­nent ba­sis start­ing Mon­day. Ferm ini­tial­ly took the in­ter­im job on Feb. 1 af­ter a string of CFO posts at such Swedish com­pa­nies as Medi­vir and Dok­tor24. In March, Im­mu­nicum filled its CMO va­can­cy with ex-Kiadis med­ical chief Jeroen Rovers.

→ Pfiz­er alum David Gray has signed on to be CSO at In­scopix, a com­pa­ny out of Pa­lo Al­to fo­cused on treat­ing neu­rode­gen­er­a­tive and neu­ropsy­chi­atric dis­eases us­ing its brain map­ping plat­form. Af­ter 15 years at Pfiz­er, the last three of those as a se­nior di­rec­tor in neu­ro, Gray then moved to Cerev­el as VP in charge of de­vel­op­ment for its Parkin­son’s and Alzheimer’s pro­grams.

→ New Jer­sey drug dis­cov­ery com­pa­ny Vyant Bio, fo­cused on neu­rol­o­gy and on­col­o­gy, has pegged Robert Fre­meau as CSO. Camp4 turned to Fre­meau — a for­mer sci­en­tif­ic di­rec­tor in neu­ro­science dur­ing his decade at Am­gen — to fill the role of se­nior di­rec­tor, trans­la­tion­al sci­ences, neu­roim­munol­o­gy in 2019 and lat­er be­came ex­ec­u­tive di­rec­tor, CNS dis­cov­ery be­fore his ex­it in Jan­u­ary.

→ At the same time as com­plet­ing its ac­qui­si­tion of Bay­on Ther­a­peu­tics, Eye­Gate Phar­ma­ceu­ti­cals has tapped Bay­on’s co-founder and di­rec­tor Er­ic Daniels as chief de­vel­op­ment of­fi­cer. Daniels al­so comes aboard from Oc­cuRx, where he was CEO. Pri­or to those roles, Daniels was co-founder and di­rec­tor of Oko­gen and served at Cy­tori Ther­a­peu­tics among oth­ers.

→ Swiss-based Celonic has named Alexan­dre Pasi­ni as COO, suc­ceed­ing Vikalp Mo­han — who will now be serv­ing as CBO. Pasi­ni joins the com­pa­ny af­ter a stint as COO at SaniSure. Pri­or to that, Pasi­ni spent over a decade at Lon­za in roles rang­ing from site di­rec­tor to head of glob­al bio­science op­er­a­tions.

→ Fol­low­ing the ap­point­ment of chief man­u­fac­tur­ing of­fi­cer Tushar Mis­ra in Au­gust, Cam­bridge, MA an­ti­body-drug con­ju­gate (ADC) play­er Mer­sana Ther­a­peu­tics has in­stalled Mo­han Bala as SVP, strate­gic prod­uct plan­ning & pro­gram lead­er­ship. Fel­low Tesaro alum Bri­an De­Schuyt­ner, who once had strate­gic prod­uct plan­ning du­ties, earns a pro­mo­tion to SVP and CFO. Bala gets a fresh start here af­ter less than a year as COO at Con­stel­la­tion Phar­ma­ceu­ti­cals, and he al­so brings Big Phar­ma cre­den­tials from J&J (Cen­to­cor), GSK and Sanofi.

→ Doug Gir­gen­ti has tak­en over as VP of drug de­vel­op­ment at Melin­ta Ther­a­peu­tics. Pri­or to join­ing Melin­ta, Gir­gen­ti led clin­i­cal de­vel­op­ment pro­grams as se­nior med­ical di­rec­tor at Ma­gen­ta Ther­a­peu­tics. Gir­gen­ti has al­so su­per­vised glob­al de­vel­op­ment pro­grams at Wyeth/Pfiz­er and Boehringer In­gel­heim.

→ Exo Ther­a­peu­tics has brought on Dorothy Lou Bai­ley as SVP, cor­po­rate de­vel­op­ment and strat­e­gy. Most no­tably, Bai­ley has served as head of cor­po­rate de­vel­op­ment at Black­thorn Ther­a­peu­tics. With its roots in David Liu’s Har­vard lab, Exo — the ex­osite-fo­cused biotech led by CEO Michael Bruce — made the news ear­li­er this month with its $78 mil­lion Se­ries B round.

→ Pen­ny stock kid­ney dis­ease play­er Uni­cy­cive Ther­a­peu­tics, which priced its IPO at $25 mil­lion af­ter orig­i­nal­ly fil­ing for a $36 mil­lion of­fer­ing, has lined up phar­ma vet Dou­glas Jer­masek as EVP, cor­po­rate strat­e­gy. Jer­masek writes a new chap­ter at Uni­cy­cive af­ter his time at Ake­bia (then Keryx af­ter the merg­er) as SVP, mar­ket­ing and strat­e­gy, and to close out 12 years at Gen­zyme from 2014, he was Sanofi’s SVP and gen­er­al man­ag­er, head of re­nal glob­al busi­ness unit.

→ Pas­cal Bam­ford is ven­tur­ing off to Akoya Bio­sciences, which start­ed a spa­tial bi­ol­o­gy part­ner­ship in June with As­traZeneca, as SVP, R&D and lab­o­ra­to­ry op­er­a­tions. Like Akoya’s COO, Fred­er­ic Pla, Bam­ford is a Ge­nom­ic Health alum, serv­ing as SVP of prod­ucts and ser­vices R&D be­fore and af­ter Ex­act Sci­ences ponied up $2.8 bil­lion to buy the com­pa­ny in the sum­mer of 2019.

→ Af­ter nab­bing reg­u­la­to­ry af­fairs and CMC ex­ecs in March, San Diego on­col­o­gy play­er Ap­tose has pro­mot­ed Janet Clen­nett to VP, fi­nance and picked up Roger Davies as VP, op­er­a­tions. Clen­nett orig­i­nal­ly moved on to Ap­tose as di­rec­tor of fi­nance af­ter her time in the same ca­pac­i­ty and as act­ing CFO at ProMIS Neu­ro­sciences. With ex­pe­ri­ence un­der his belt at CROs (Icon) and phar­ma gi­ants (No­var­tis), Davies comes off a three-year stay with In­ter­cept in clin­i­cal op­er­a­tions.

→ Lu­micks, a Dutch provider of sin­gle mol­e­cule and cell avid­i­ty analy­sis, has pulled in Joshua Young as VP of in­vestor re­la­tions, com­mu­ni­ca­tions and strat­e­gy. Once the head of in­vestor re­la­tions at Mer­ck KGaA, Young comes to Lu­micks af­ter a short tenure as the VP of in­vestor re­la­tions at Ever­bridge.

→ What’s next for Tal Zaks af­ter leav­ing Mod­er­na and join­ing the board at Te­va? He’ll be rolling in the Deep as he gets a spot on the strate­gic ad­vi­so­ry board at Deep Ge­nomics, Bren­dan Frey’s Toron­to-based AI and ma­chine learn­ing shop that has a boat­load of new cash in the form of a $180 mil­lion Se­ries C from Ju­ly to push its batch of RNA ther­a­pies to the clin­ic. Since Zaks’ de­par­ture as CMO, Mod­er­na has tak­en more heat for the lack of avail­abil­i­ty of its Covid-19 vac­cine in low­er- and mid­dle-in­come coun­tries, which the biotech tried to ame­lio­rate this week by ramp­ing up pro­duc­tion for the African Union.

→ Run­ning along­side its $100 mil­lion Se­ries C from ear­li­er in the week, New York an­ti-ag­ing biotech Cam­bri­an Bio­phar­ma has wel­comed one of its in­vestors, ex-Al­ler­gan CEO Brent Saun­ders, to the board of di­rec­tors. Saun­ders, who chairs the board at lit­tle-known OcuTer­ra, “hit it off” with CEO James Pey­er, as our Ja­son Mast notes. Paul Farr, a part­ner at An­thos Cap­i­tal — which co-led the round with SALT Fund — al­so takes a seat on Cam­bri­an’s board.

→ Scott My­ers is hav­ing him­self a week. Not on­ly has he been named chair­man at Har­poon, he has re­placed An­drew Hack as chair­man of the board at Dy­navax — since May 2020, Hack had chaired the vac­cine biotech on an in­ter­im ba­sis. My­ers, the CEO of AM­AG Phar­ma­ceu­ti­cals for a hot sec­ond un­til it was ac­quired by Co­vis last fall, is on the boards of Se­lec­ta Bio­sciences and Tril­li­um Ther­a­peu­tics, which Pfiz­er bought out for $2.3 bil­lion in Au­gust.

→ Neil Ku­mar’s crew at Bridge­Bio, which is part­ner­ing with Bris­tol My­ers to ex­plore a drug com­bo in­volv­ing Op­di­vo and SHP2 in­hibitor BBP-398, has named Han­nah Valan­tine to the board of di­rec­tors. Valan­tine, a pro­fes­sor at the Stan­ford Uni­ver­si­ty School of Med­i­cine, was the first chief of­fi­cer for sci­en­tif­ic work­force di­ver­si­ty at the NIH from 2014-20.

→ Bris­tol My­ers’ glob­al R&D chief Ru­pert Vessey has been elect­ed to the board of di­rec­tors at Nereid Ther­a­peu­tics, part of a bio­mol­e­c­u­lar con­den­sate field that al­so in­cludes Dew­point and Faze Med­i­cines. NewYork-Pres­by­ter­ian Hos­pi­tal EVP and COO Lau­ra Forese is join­ing Vessey on Nereid’s board.

→ Boston-based BY­OMass has re­cruit­ed De­clan Doogan and Stephen Hoff­man to its board of di­rec­tors. Doogan is the CMO and co-founder of Ju­ve­nes­cence, while Hoff­man most re­cent­ly served as CRO of Aer­pio Phar­ma­ceu­ti­cals. Be­sides his stint at Ju­ve­nes­cence, Doogan is the chair­man and co-founder of Bio­haven Phar­ma­ceu­ti­cals and pre­vi­ous­ly worked with Pfiz­er and Amarin. Mean­while, this isn’t Hoff­man’s first board ap­point­ment. He al­so sits on the boards of Acel­Rx Phar­ma­ceu­ti­cals, Dicer­na Phar­ma­ceu­ti­cals, Dan­forth Ad­vi­sors, and Apic Bio.

→ Ve­rastem On­col­o­gy has made room for Michelle Robert­son on the board of di­rec­tors. Robert­son, the CFO for Jim Mullen at Ed­i­tas Med­i­cine, has al­so been CFO for Mo­men­ta be­fore it was sold to J&J in 2020.

→ Speak­ing of Ed­i­tas, Bernadette Con­naughton has joined the board of di­rec­tors — one that al­so in­cludes C4 CEO An­drew Hirsch and the newest board mem­ber at Were­wolf Ther­a­peu­tics, Leg­end SVP Mee­ta Chat­ter­jee. Con­naughton, a long­time Bris­tol My­ers ex­ec who left in 2017 as pres­i­dent, in­ter­con­ti­nen­tal, has board seats at Sy­neos Health, Zealand Phar­ma and Halozyme.

→ Han­mi Sci­ence CEO Jong-yoon Lim has been tapped as a reg­is­tered di­rec­tor of Ox­ford Vacmedix. Pri­or to his cur­rent role at Han­mi Sci­ence, Lim was CEO of Han­mi Phar­ma­ceu­ti­cals and head of Bei­jing Han­mi Pharm.

→ HCW Bi­o­log­ics has brought on Lisa Giles and Gary Win­er to its board of di­rec­tors. Giles is the man­ag­ing di­rec­tor and CEO of Giles & As­so­ci­ates Con­sul­tan­cy and cur­rent­ly sits on the board of Mile­stone Phar­ma­ceu­ti­cals. Ear­li­er in her ca­reer, Giles served at Ab­bott Lab­o­ra­to­ries. Mean­while, Win­er pre­vi­ous­ly served as pres­i­dent and CEO of Or­gen­tec Di­ag­nos­ti­ka. Ear­li­er in his ca­reer, Win­er held stints at Ab­bott and was VP of glob­al com­mer­cial strate­gies at Ab­b­Vie and pres­i­dent and CEO of Ab­b­Vie Japan.

→ Jonathan Arnold, Catal­ent’s pres­i­dent, oral and spe­cial de­liv­ery, has joined the board of di­rec­tors of AN­GUS Chem­i­cal Com­pa­ny. Pri­or to his cur­rent po­si­tion at Catal­ent, Arnold served as VP and gen­er­al man­ag­er of the com­pa­ny’s drug de­liv­ery so­lu­tions busi­ness unit. Pri­or to Catal­ent, Arnold was with Pan­theon.

→ Synen­dos Ther­a­peu­tics has ap­point­ed the fol­low­ing mem­bers to its sci­en­tif­ic ad­vi­so­ry board: Karl-Heinz Alt­mann, Anahi­ta Bassir Nia, Graeme Bilbe, Jürg Gertsch, and Kirsten Müller-Vahl. In No­vem­ber of last year, the Swiss-based start­up raised $21.85 mil­lion in Se­ries A fi­nanc­ing to de­vel­op ther­a­pies for neu­ropsy­chi­atric dis­or­ders.